Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Cuts Spending in Q2 as Revenue Plunges 27 Percent

NEW YORK (GenomeWeb News) — CombiMatrix today said that second-quarter revenue plunged 27 percent as R&D spending was cut nearly in half and net loss widened 5 percent.
 
Total receipts for the three months ended June 30 decreased to $1.3 million from $1.8 million during the same period last year.
 
Product sales declined 60 percent to $458,000; government contract revenue rose 20 percent to $680,000; and service revenue was up more than 230 percent to $199,000 from $60,000.
 
R&D spending fell to $1.1 million from $2.2 million. The numbers include non-cash stock compensation expense of $144,000 for the second quarter of 2007 and $193,000 for the second quarter of 2006.
 
Net loss increased to $3.6 million from $3.4 million year over year.
 
CombiMatrix had around $12.8 million in cash, equivalents, and short term investments as of June 30.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.